Ingredient or product comparison
GHK-Cu Research Protocols: Topical vs Subcutaneous Administration
Researchers investigating GHK-Cu for dermatological applications use two primary delivery methods: topical formulations (creams, serums, microneedling solutions) and subcutaneous injections. Each route presents distinct pharmacokinetic challenges relevant to h
This source-based comparison does not add ratings or recommend a winner.
- Researchers investigating GHK-Cu for dermatological applications use two primary delivery methods: topical formulations (creams, serums, microneedling solutions) and subcutaneous injections. Each route presents distinct pharmacokinetic challenges relevant to hair-growth research.
- Topical delivery requires penetration enhancers to cross the stratum corneum. Common formulation strategies include liposomal encapsulation (lipid vesicles that fuse with skin membranes), chemical enhancers like DMSO or propylene glycol (which disrupt lipid bilayers), and microneedling (creating microchannels 0.5–1.5mm deep that bypass the barrier). A 2019 formulation study in the International Journal of Cosmetic Science compared GHK-Cu delivery across vehicle types: liposomal formulations achieved 12% dermal penetration vs 3% in standard aqueous solutions. Microneedling combined with topical application increased penetration to 18–22%, though this introduces tissue trauma that may independently stimulate wound-healing pathways.
- Subcutaneous administration delivers peptide directly to dermal tissue, bypassing absorption barriers entirely. Research protocols typically inject 0.5–2mg GHK-Cu per site using insulin syringes, targeting areas of visible thinning with 1cm spacing between injection points. Peptide half-life after subcutaneous dosing is approximately 2–4 hours based on copper-peptide pharmacokinetics, requiring frequent administration (daily or every other day) to maintain tissue levels. No published studies have compared subcutaneous GHK-Cu to topical delivery for hair-density outcomes. Researchers currently extrapolate from wound-healing protocols.
- Dosing consistency remains a major variable. Commercial topical products list GHK-Cu concentrations ranging from 200 μg/mL to 30 mg/mL. A 150-fold difference. In-vitro studies show dose-dependent effects peaking at 5–10 μM (roughly 1.7–3.4 mg/mL), but translating this to effective scalp concentrations requires knowing how much peptide remains bioactive after formulation, how deeply it penetrates, and how quickly it degrades in situ. Copper-peptide complexes are pH-sensitive and oxidize rapidly at pH >7.0, losing activity within 24–48 hours if improperly stored.
- Topical (aqueous)
- Stratum corneum only
- 1–3% dermal
- Daily application
- None
- In-vitro + permeation studies
- Topical (liposomal)
- Upper dermis
- 7–12% dermal
- Formulation studies
- Microneedling + topical
- Mid-dermis (0.5–1.5mm)
- 18–22% dermal
- Weekly microneedling + daily topical
- Controlled microtrauma
- Case series (non-controlled)
- Subcutaneous injection
- Direct dermal delivery
- Near 100% local
- Daily to every-other-day
- Injection site reactions
- Wound-healing models (animals)
- Oral supplementation
- Systemic (indirect)
- Unknown follicular
- Daily
- No hair-specific data